Redeye noted that BeammWave's Q1 2025 report significantly exceeded expectations, primarily due to r...
Redeye stated InfraCom's Q1 2025 report provided further evidence that the company has overcome exec...
Redeye returns with positive estimate adjustments following GomSpace’s trading update that beat our ...
Redeye comments on Active Biotech’s Q1 report 2025.
Redeye retains its Base Case and makes minor forecast adjustments following the full Q1 report, with...
Redeye retains its positive view of Transtema following a Q1 report with strong growth but a slightl...
STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.
Redeye embraces the news of AroCell’s expanded cooperation with Concile to reach markets outside Ger...
AcuCort (”AcuCort” eller ”Bolaget”) har publicerat Bolagets delårsrapport för det första kvartalet 2...
Alzecure har på senare tid stärkt profilen för bolagets ledande projekt, ACD856, genom att visa data...
Redeye's provides its initial take on Xbrane's Q1 report which confirmed a stronger than anticipated...
Kontraktstillverkaren Hanza levererade för tredje kvartalet i rad en stark rapport med förbättrade m...
Redeye notes that Paxman completes the offer to Dignitana.
Redeye comments on I-Tech’s Q1 figures that beat our estimates across the board, delivering growth o...
Redeye comments on Transtema’s Q1 report, showing strong organic growth in Sweden but a relatively s...
Redeye comments on Tessin’s Q1 results, which came in much weaker than expected.
Sales 2% higher than expected; 24% y-o-y FX adjusted But higher investments increased lead to miss o...
Redeye noted InfraCom's robust profitability, surpassing its EBITDA estimate by 21%.
Redeye comments on Truecaller’s Q1 2025 report, which was somewhat softer than expected.
Redeye comments on Xspray following an undramatic Q1 report.
